How should I assess and treat a patient presenting with tachycardia, including criteria for hemodynamic stability and management options for stable supraventricular tachycardia, atrial fibrillation/flutter, and sinus tachycardia?

Assessment and Management of Tachycardia

Hemodynamic stability determines your immediate pathway: unstable patients require immediate synchronized cardioversion, while stable patients proceed through a stepwise algorithm based on rhythm type. 1

Immediate Assessment of Hemodynamic Stability

Assess for these critical signs that mandate immediate cardioversion 1:

• Hypotension (systolic BP <90 mmHg)
• Altered mental status or signs of shock
• Acute chest pain suggesting ischemia
• Acute heart failure symptoms (pulmonary edema, severe dyspnea)

Obtain a 12-lead ECG immediately to differentiate rhythm types and rule out ventricular tachycardia or pre-excited atrial fibrillation—administering AV nodal blockers in these conditions can cause hemodynamic collapse or ventricular fibrillation. 1

Management of Hemodynamically UNSTABLE Tachycardia

Proceed directly to synchronized cardioversion for any patient showing hemodynamic instability—this achieves 100% conversion in unstable SVT cases. 1, 2

Do not delay for pharmacologic interventions when vital organ hypoperfusion is present. 3

Management of Hemodynamically STABLE Supraventricular Tachycardia

Step 1: Vagal Maneuvers (First-Line)

Attempt vagal maneuvers immediately—they are quick, safe, and achieve conversion in approximately 31% of cases. 1

• Modified Valsalva maneuver is more successful than carotid massage (27.7% overall success when switching between techniques). 1
• These maneuvers help diagnostically even when unsuccessful. 1

Step 2: Adenosine (Second-Line)

Adenosine is the next intervention with 90-95% conversion rate for AVNRT and AVRT. 1, 4

• Administer as rapid IV bolus via proximal vein followed immediately by saline flush. 1
• Effective in 91% of stable SVT cases. 4

Step 3: Alternative Pharmacologic Agents

IV diltiazem or verapamil are highly effective for AVNRT conversion (80-98% success), but are absolutely contraindicated if any possibility of ventricular tachycardia, pre-excited atrial fibrillation, or systolic heart failure. 1, 5

IV beta blockers (metoprolol 5 mg over 1-2 minutes, repeated every 5 minutes to maximum 15 mg; or esmolol 500 mcg/kg over 1 minute followed by infusion) are a reasonable alternative with excellent safety profile, though less effective than calcium channel blockers. 5, 6, 1

Critical contraindications to beta blockers include 6:

• Pre-excited atrial fibrillation or Wolff-Parkinson-White syndrome with AF/flutter
• Active asthma or reactive airways disease
• Decompensated heart failure
• Second- or third-degree heart block or PR interval >0.24 seconds

Amiodarone (150 mg over 10 minutes, repeated if necessary, followed by 1 mg/min infusion for 6 hours, then 0.5 mg/min) is an option for stable irregular narrow-complex tachycardia or when other agents fail. 5

Management of Stable Atrial Fibrillation/Flutter with Rapid Ventricular Rate

Rate control is the priority in hemodynamically stable patients without pre-excitation. 2

First-line agents for rate control 5, 2:

• IV beta blockers (metoprolol or esmolol as above)
• IV diltiazem or verapamil (avoid in systolic heart failure)
• IV amiodarone (150 mg over 10 minutes)

Never use AV nodal blockers (beta blockers, calcium channel blockers, digoxin, adenosine) in pre-excited atrial fibrillation—this can precipitate ventricular fibrillation. 5, 1

For pre-excited atrial fibrillation, use procainamide (20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS prolonged by 50%, or total dose 17 mg/kg) or consider immediate cardioversion. 5

Management of Sinus Tachycardia

Identify and treat the underlying cause—sinus tachycardia is a physiologic response, not a primary arrhythmia requiring direct treatment. 3

Common causes to address:

• Hypovolemia/dehydration (fluid resuscitation)
• Pain (analgesia)
• Fever/infection (antipyretics, antibiotics)
• Hypoxia (oxygen supplementation)
• Anemia (transfusion if indicated)
• Thyrotoxicosis (beta blockers for symptom control)
• Medications/stimulants (discontinue offending agents)

Rate control with beta blockers may be appropriate for symptomatic inappropriate sinus tachycardia after excluding secondary causes, but this is a diagnosis of exclusion.

Post-Conversion Management and Definitive Therapy

Be prepared for immediate reinitiation of SVT from atrial or ventricular premature complexes after successful conversion—may require antiarrhythmic drug to prevent recurrence. 1

Catheter ablation is first-line definitive therapy for symptomatic paroxysmal SVT with single-procedure success rates of 94.3-98.5% and cure rates >90-95%. 6, 4

Oral beta blockers, diltiazem, or verapamil are Class I recommendations for long-term suppression of recurrent paroxysmal SVT in symptomatic patients who decline ablation or are not candidates. 6

Educate patients on performing vagal maneuvers for future episodes and arrange cardiology follow-up for consideration of catheter ablation. 1

Critical Pitfalls to Avoid

Do not misdiagnose wide-complex tachycardia as SVT—the most costly mistake is over-diagnosis of SVT when ventricular tachycardia is present; when in doubt, treat as VT. 3

Do not use digoxin for acute management—its slow onset of action and relatively low potency render it less useful for treatment of acute arrhythmias. 5

Do not use AV nodal blockers without confirming absence of pre-excitation on ECG—this can be fatal in Wolff-Parkinson-White syndrome with atrial fibrillation. 5, 6, 1